Skip to main content
SpringerLink
Log in

Glycoxidation and Diabetic Complications: Modern Lessons and a Warning?

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;7:1167-1172.

    Google Scholar 

  2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.

    Google Scholar 

  3. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977.

    Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853.

    Google Scholar 

  5. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001;10(11):1977-1987.

    Google Scholar 

  6. Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation: A new risk factor for cardiovascular disease? (Review). Cardiovascular Toxicology 2002;2(4):275-287.

    Google Scholar 

  7. Lee T, Kimiagar M, Pintauro SJ, Chichester CO. Physiological and safety aspects of Maillard browning of foods. Prog Food Nutr Sci 1981;5:243-256.

    Google Scholar 

  8. O'Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 1989;28:211-248.

    Google Scholar 

  9. Henle T. A food chemist's view of advanced glycation end-products. Perit Dial Int 21 2001;(Suppl 3):S125-130.

    Google Scholar 

  10. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive advanced glycation end products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474-6479.

    Google Scholar 

  11. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308-1315.

    Google Scholar 

  12. Goldberg T, Cai W, Peppa M, Dardaine V, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc (in press).

  13. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344(1):109-116.

    Google Scholar 

  14. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9(2):69-77.

    Google Scholar 

  15. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271(17):9982.

    Google Scholar 

  16. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.

    Google Scholar 

  17. Miyata T, Ishikawa N, van Ypersele de Strihou C. Carbonyl stress and diabetic complications. Clin Chem Lab Med 2003;41(9):1150-1158.

    Google Scholar 

  18. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987;245(1):243-250.

    Google Scholar 

  19. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404(6779):787-790.

    Google Scholar 

  20. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995;270(18):10828-10832.

    Google Scholar 

  21. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 1999;55(2):389-399.

    Google Scholar 

  22. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glycosylation and glucose-dependent cross-linking of proteins. J Biol Chem 1983;258:9406-9412.

    Google Scholar 

  23. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products:A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84(5):489-497.

    Google Scholar 

  24. Cohn JS. Oxidized fat in the diet, post-prandial lipaemia and cardiovascular disease. Curr Opin Lipidol 2002;13:19-24.

    Google Scholar 

  25. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield E. Inflammatory markers are induced by dietary glycotoxins: A pathway for accelerated atherosclerosis in diabetes. Proc Natl Acad Sci 2002;99(24):15596-15601.

    Google Scholar 

  26. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H. Restriction of dietary glycotoxins markedly reduces AGE toxins in renal failure patients. J Am Soc Nephrol 2003;14(3):728-731.

    Google Scholar 

  27. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17(6):436-443.

    Google Scholar 

  28. Uribarri J, Cai W, Peppa M, Goldberg T, Vlassara H. Renal clearance of advanced glycoxidation end products (AGE) is markedly reduced in diabetic patients in the absence of impaired GFR. J Am Soc Nephrol 2003;14:394A.

    Google Scholar 

  29. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycation end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:140-160.

    Google Scholar 

  30. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998;101(5):1142-1147.

    Google Scholar 

  31. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996;93(20):11047-11052.

    Google Scholar 

  32. He CJ, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001;7(3):159-168.

    Google Scholar 

  33. Lu CY, He CJ, Cai WJ, Vlassara H. Overexpression of AGE-R1 inhibits AGE-induced MAPK and NF-kB activations in murine mesangial cells. Diabetes 2003;52(Suppl 1):A50(abstract).

    Google Scholar 

  34. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol Med 1995;1(6):634-646.

    Google Scholar 

  35. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108(2):261-268.

    Google Scholar 

  36. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995;1(10):1057-1061.

    Google Scholar 

  37. Zheng F, Cai W, Mitsuhashi T, Vlassara H. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: A potential AGE sequestration therapy for diabetic nephropathy? Mol Med 2001;7(11):737-747.

    Google Scholar 

  38. Cai W, Cao Q, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction. Mol Med 2002;8(7):337-346.

    Google Scholar 

  39. Cai W, He C, Zhu L, Peppa M, Lu C, Vlassara H. Dietary-AGE-modified LDL is a potent redox-sensitive MAPk stimulant in diabetic patients. Circulation (in press).

  40. Lin RY, Reis ED, Dore AT, Lu M, Ghodsi N, Fallon JT, Fisher EA, Vlassara H. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002;163(2):303-311.

    Google Scholar 

  41. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, Vlassara H. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003;168:213-220.

    Google Scholar 

  42. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002;18(3):224-237.

    Google Scholar 

  43. Sebekova K, Faist V, Hofmann T, Schinzel R, Heidland A. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 2003;41(3 Suppl 1):S48-51.

    Google Scholar 

  44. Peppa M, Brem H, Ehrlich P, Zhang J, Cai W, Li Z, Croitoru A, Thung S, Vlassara H. Adverse effects of dietary glycotoxins in genetically diabetic mice. Diabetes 2003;52:2805-2813.

    Google Scholar 

  45. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, Vlassara H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002;51(7):2082-2089.

    Google Scholar 

  46. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003;52(6):1441-1448.

    Google Scholar 

  47. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20(5):493-510.

    Google Scholar 

  48. Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li YM, Bucala R, Vlassara H. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs. Mol Med 1997;3(9):617-627.

    Google Scholar 

  49. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998;141(1):61-75.

    Google Scholar 

  50. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25(6):1055-1059.

    Google Scholar 

  51. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340(8828):1111-1115.

    Google Scholar 

  52. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, de-Groof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104(13):1464-1470.

    Google Scholar 

  53. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kid Dis 2004;43:690-695.

    Google Scholar 

  54. Wittmann I, Wagner Z, Mazak I et al. Foods rich in advanced glycation end products (AGEs) induce microalbuminuria in healthy persons. Nephrol Dial Transplan 2001;16:106A (abstract)

    Google Scholar 

  55. Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med 2003;115(Suppl 8A):12S-19S.

    Google Scholar 

  56. Uribarri J, Peppa M, Cai W, Goldberg T, Baliga S, Lu M, Vassalotti JA, Vlassara H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kid Dis 2003;42(3):532-538.

    Google Scholar 

  57. Stirban A, Sander D, Buenting CE, Ruetter R, Ziegler D, Vlassara H, Koschinsky T. Food advanced glycation endproducts (AGE) acutely impair endothelial function in patients with diabetes mellitus (DM). Diabetes 2003;52(Suppl 1):A19 (abstract).

    Google Scholar 

  58. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutter JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure.DASH Collaborative Research Group. N Engl J Med 1997;336:1117-1124.

    Google Scholar 

  59. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IS, Kotchen TA, Lichtenstein AH, Mitch WE, Muilis R, Robinson K, Wylie-Rosett J, ST Joer S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000;102:2284-2299.

    Google Scholar 

  60. American Cancer Society/World Health Organization Food. Nutrition and the prevention of cancer: A global perspective. Washington, DC: National Academy Press, 1997.

    Google Scholar 

  61. Willet WC. Goals for nutrition in the year 2000. CA Cancer J Clin 1999;49:333-352.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY

    Helen Vlassara

  2. Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY

    Jaime Uribarri

Authors
  1. Helen Vlassara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaime Uribarri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlassara, H., Uribarri, J. Glycoxidation and Diabetic Complications: Modern Lessons and a Warning?. Rev Endocr Metab Disord 5, 181–188 (2004). https://doi.org/10.1023/B:REMD.0000032406.84813.f6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:REMD.0000032406.84813.f6

Search

Navigation